vs
Karat Packaging Inc.（KRT）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是Karat Packaging Inc.的1.1倍（$127.1M vs $115.6M），再鼎医药同比增速更快（17.1% vs 13.7%），Karat Packaging Inc.自由现金流更多（$15.1M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 10.0%）
Karat Packaging Inc.是专业一次性餐饮包装产品生产商及分销商，产品涵盖纸塑杯、食品容器、餐具、杯盖及定制品牌包装方案，主要服务北美地区的连锁餐厅、咖啡馆、餐饮服务商及零售食品客户。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
KRT vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.1倍
$115.6M
营收增速更快
ZLAB
高出3.4%
13.7%
自由现金流更多
KRT
多$41.8M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
10.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $115.6M | $127.1M |
| 净利润 | $6.8M | — |
| 毛利率 | 34.0% | 51.0% |
| 营业利润率 | 7.3% | -54.6% |
| 净利率 | 5.9% | — |
| 营收同比 | 13.7% | 17.1% |
| 净利润同比 | 21.3% | — |
| 每股收益（稀释后） | $0.34 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KRTZLAB
| Q4 25 | $115.6M | $127.1M | ||
| Q3 25 | $124.5M | $115.4M | ||
| Q2 25 | $124.0M | $109.1M | ||
| Q1 25 | $103.6M | $105.7M | ||
| Q4 24 | $101.6M | $108.5M | ||
| Q3 24 | $112.8M | $101.8M | ||
| Q2 24 | $112.6M | $100.1M | ||
| Q1 24 | $95.6M | $87.1M |
净利润KRTZLAB
| Q4 25 | $6.8M | — | ||
| Q3 25 | $7.3M | $-36.0M | ||
| Q2 25 | $10.9M | $-40.7M | ||
| Q1 25 | $6.4M | $-48.4M | ||
| Q4 24 | $5.6M | — | ||
| Q3 24 | $9.1M | $-41.7M | ||
| Q2 24 | $9.1M | $-80.3M | ||
| Q1 24 | $6.2M | $-53.5M |
毛利率KRTZLAB
| Q4 25 | 34.0% | 51.0% | ||
| Q3 25 | 34.5% | 59.5% | ||
| Q2 25 | 39.6% | 60.6% | ||
| Q1 25 | 39.3% | 63.6% | ||
| Q4 24 | 39.2% | 61.5% | ||
| Q3 24 | 38.6% | 64.1% | ||
| Q2 24 | 38.5% | 64.9% | ||
| Q1 24 | 39.3% | 61.4% |
营业利润率KRTZLAB
| Q4 25 | 7.3% | -54.6% | ||
| Q3 25 | 6.9% | -42.3% | ||
| Q2 25 | 13.3% | -50.3% | ||
| Q1 25 | 7.5% | -53.3% | ||
| Q4 24 | 7.2% | -62.6% | ||
| Q3 24 | 10.0% | -66.6% | ||
| Q2 24 | 9.9% | -76.0% | ||
| Q1 24 | 8.4% | -80.7% |
净利率KRTZLAB
| Q4 25 | 5.9% | — | ||
| Q3 25 | 5.9% | -31.2% | ||
| Q2 25 | 8.8% | -37.3% | ||
| Q1 25 | 6.2% | -45.8% | ||
| Q4 24 | 5.5% | — | ||
| Q3 24 | 8.1% | -40.9% | ||
| Q2 24 | 8.1% | -80.2% | ||
| Q1 24 | 6.4% | -61.4% |
每股收益（稀释后）KRTZLAB
| Q4 25 | $0.34 | $-0.05 | ||
| Q3 25 | $0.36 | $-0.03 | ||
| Q2 25 | $0.54 | $-0.04 | ||
| Q1 25 | $0.32 | $-0.04 | ||
| Q4 24 | $0.28 | $-0.09 | ||
| Q3 24 | $0.45 | $-0.04 | ||
| Q2 24 | $0.45 | $-0.08 | ||
| Q1 24 | $0.31 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $37.9M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $149.4M | $715.5M |
| 总资产 | $287.7M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资KRTZLAB
| Q4 25 | $37.9M | $689.6M | ||
| Q3 25 | $44.0M | $717.2M | ||
| Q2 25 | $57.0M | $732.2M | ||
| Q1 25 | $56.3M | $757.3M | ||
| Q4 24 | $59.9M | $779.7M | ||
| Q3 24 | $60.4M | $616.1M | ||
| Q2 24 | $52.1M | $630.0M | ||
| Q1 24 | $46.7M | $650.8M |
股东权益KRTZLAB
| Q4 25 | $149.4M | $715.5M | ||
| Q3 25 | $154.5M | $759.9M | ||
| Q2 25 | $155.8M | $791.7M | ||
| Q1 25 | $153.3M | $810.8M | ||
| Q4 24 | $155.6M | $840.9M | ||
| Q3 24 | $157.3M | $667.7M | ||
| Q2 24 | $157.7M | $704.2M | ||
| Q1 24 | $154.4M | $762.2M |
总资产KRTZLAB
| Q4 25 | $287.7M | $1.2B | ||
| Q3 25 | $302.8M | $1.2B | ||
| Q2 25 | $321.0M | $1.2B | ||
| Q1 25 | $312.2M | $1.2B | ||
| Q4 24 | $294.5M | $1.2B | ||
| Q3 24 | $306.8M | $985.3M | ||
| Q2 24 | $310.7M | $987.4M | ||
| Q1 24 | $279.0M | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $15.4M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $15.1M | $-26.7M |
| 自由现金流率自由现金流/营收 | 13.1% | -21.0% |
| 资本支出强度资本支出/营收 | 0.2% | 0.5% |
| 现金转化率经营现金流/净利润 | 2.26× | — |
| 过去12个月自由现金流最近4个季度 | $33.1M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流KRTZLAB
| Q4 25 | $15.4M | $-26.0M | ||
| Q3 25 | $982.0K | $-32.0M | ||
| Q2 25 | $9.8M | $-31.0M | ||
| Q1 25 | $7.7M | $-61.7M | ||
| Q4 24 | $8.3M | $-55.8M | ||
| Q3 24 | $19.5M | $-26.8M | ||
| Q2 24 | $13.7M | $-42.2M | ||
| Q1 24 | $6.6M | $-90.1M |
自由现金流KRTZLAB
| Q4 25 | $15.1M | $-26.7M | ||
| Q3 25 | $736.0K | $-35.0M | ||
| Q2 25 | $9.6M | $-33.9M | ||
| Q1 25 | $7.6M | $-63.2M | ||
| Q4 24 | $8.0M | $-58.4M | ||
| Q3 24 | $19.2M | $-28.2M | ||
| Q2 24 | $13.4M | $-42.9M | ||
| Q1 24 | $6.4M | $-91.1M |
自由现金流率KRTZLAB
| Q4 25 | 13.1% | -21.0% | ||
| Q3 25 | 0.6% | -30.4% | ||
| Q2 25 | 7.7% | -31.1% | ||
| Q1 25 | 7.4% | -59.9% | ||
| Q4 24 | 7.9% | -53.8% | ||
| Q3 24 | 17.0% | -27.7% | ||
| Q2 24 | 11.9% | -42.9% | ||
| Q1 24 | 6.7% | -104.5% |
资本支出强度KRTZLAB
| Q4 25 | 0.2% | 0.5% | ||
| Q3 25 | 0.2% | 2.6% | ||
| Q2 25 | 0.1% | 2.6% | ||
| Q1 25 | 0.1% | 1.5% | ||
| Q4 24 | 0.2% | 2.4% | ||
| Q3 24 | 0.3% | 1.3% | ||
| Q2 24 | 0.2% | 0.7% | ||
| Q1 24 | 0.2% | 1.1% |
现金转化率KRTZLAB
| Q4 25 | 2.26× | — | ||
| Q3 25 | 0.13× | — | ||
| Q2 25 | 0.89× | — | ||
| Q1 25 | 1.21× | — | ||
| Q4 24 | 1.47× | — | ||
| Q3 24 | 2.14× | — | ||
| Q2 24 | 1.50× | — | ||
| Q1 24 | 1.06× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KRT
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
